glp-1 pharmacology and Anesthesia: Considerations and Cautions for CRNAs Emerging Trends in the Development

Most require a BMI of 30 or higher, obesity-related conditions, and prior authorization

He now specializes in evidence-based weight management, including GLP-1/GIP therapies (semaglutide & tirzepatide)

The SCORE2 Asia-Pacific algorithms have been calibrated to estimate the 10-year risk of CVD in apparently healthy people in Asia and Oceania

[DOI] [PubMed] [Google Scholar] [63].Knudsen LB, Nielsen PF, Huusfeldt PO, Johansen NL, Madsen K, Pedersen FZ, Thogersen H, Wilken M, Agerso H, Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration, Journal of medicinal chemistry, 43 (2000) 16641669